BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...
The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...
As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra to treat patients in an increasingly competitive indication—transthyret | ...
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on BBIO stock, giving a Buy rating on January 14. Tyler Van Buren has given his Buy rating due to a combination of factors ...
GlobalData on MSN5d
EC grants marketing authorisation to BridgeBio’s ATTR-CM treatmentThe European Commission (EC) has granted marketing authorisation to BridgeBio Pharma’s selective small molecule, acoramidis, ...
In this article, we will discuss the 12 Best Healthcare Stocks to Buy According to Analysts. McKinsey reported that, since ...
8don MSN
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where BridgeBio Pharma, Inc.
The company's drug, Attruby, designed to treat ATTR-CM, a progressive fatal heart disease, has seen substantial demand since its FDA approval, with 430 prescriptions written by 248 unique ...
In other recent news, BridgeBio Pharma has made significant strides with its late-stage pipeline programs. The company's drug, Attruby, designed to treat ATTR-CM, a progressive fatal heart disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback